Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland.

Paul M McKeigue Duncan Porter Rosemary J Hollick Stuart H Ralston David A McAllister Helen Martina Colhoun

Published in: Scandinavian journal of rheumatology (2022)

The risk of hospitalized COVID-19 is elevated in IRD patients treated with immunosuppressive drugs compared with the general population. Of these drugs, methotrexate, hydroxychloroquine, and TNF inhibitors carry the lowest risk. The highest risk is associated with prednisolone. A larger study is needed to estimate reliably the risks associated with each class of targeted DMARD.

Keyphrases

coronavirus disease
sars cov
rheumatoid arthritis
high dose
cancer therapy
stem cells
respiratory syndrome coronavirus
risk assessment
cell therapy
chemotherapy induced